In a rare example of a university tec transfer deal attracting an upfront payment, French pharma company Ipsen paying €1.25 million for a treatment licence.
Innate Pharma SA has applied for an initial public offering and listing on the Euronext in Paris, to raise funds to expand its pipeline of oncology therapeutics.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.